Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper

Industry Insight by 2FIRSTS
Apr.15.2024
Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
JAMA retracts e-cigarette quitting study for major coding errors and doubts on accuracy, causing widespread concern and controversy.

Recently, the Journal of the American Medical Association (JAMA) retracted an article published two months ago about vaping e-cigarettes due to researchers notifying the editors of "significant coding errors" and other issues in the study.

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal page | Image source: American Medical Association Journal

 

This paper titled "Effectiveness of e-cigarettes compared with varenicline and nicotine gum for smoking cessation: a randomized clinical trial" was originally published in the January 29th issue of JAMA Internal Medicine, led by Dr. Liu Zhaobo from the Smoking Control and Respiratory Disease Prevention Department at Beijing Friendship Hospital. The researchers in this study found that in terms of helping people quit smoking, using e-cigarettes is not inferior to prescription medications and is more effective than nicotine gum. The paper has garnered widespread attention in the medical community, non-professional media, and social media.

 

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal notice | Image source: Journal of the American Medical Association

 

However, the article was later retracted.

 

The retraction notice for this paper was issued on March 29th as follows:

 

We have identified significant coding errors that are difficult to correct. We also found discrepancies in the calculations, which have raised doubts about the accuracy and reliability of the reported results. Therefore, we believe it is necessary to retract this article in order to maintain the integrity of scientific research and uphold the trust of our readers and the medical community. All co-authors have agreed to the retraction. We sincerely apologize for any inconvenience or confusion this may have caused.

 

According to the academic media Research Gate, Liu Zhao later responded to media inquiries via email, stating that the article was voluntarily retracted by the research team. He provided the following explanation in response:

 

As we explained to the editors of the Journal of the American Medical Association, following the publication of this paper, we plan to conduct a secondary analysis. In this process, we discovered that 109 participants who should have been in the NRT group were incorrectly placed in the EC group, and another 109 participants who should have been in the EC group were incorrectly placed in the NRT group. We immediately conducted an analysis and found that the main results had changed, therefore, we promptly wrote a letter to the editor explaining this issue and requesting the retraction of the paper.

 

Furthermore, according to publicly available information, no other articles have been affected by these issues. According to Clarivate's Web of Science, the research findings in question have been cited once.

 

Dr. Liu Chaobo, the first author of the paper by the group called 2FIRSTS, was contacted for details regarding the withdrawal notice. Dr. Liu stated that the withdrawal notice was clearly explained and no further information could be disclosed. Additionally, a call was made to the Tobacco Control and Cessation Center at the China-Japan Friendship Hospital to inquire about the details, but the staff member who answered the call claimed to be unaware of the situation.

 

2FIRSTS will continue to follow the latest developments on the research paper and its retraction.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan, Ph.D., has been named a 2026 Fellow of the Society for Research on Nicotine and Tobacco (SRNT), an international professional association dedicated to advancing nicotine and tobacco research. Fellows are selected for outstanding research contributions as well as leadership, mentoring, and policy engagement within the field.
Feb.23
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Bill 221 (SB 221), which seeks to regulate the retail sale of nicotine products, has passed the Senate Health and Human Services Committee with a unanimous 7–0 recommendation. The bill was significantly amended, expanding from three to nine pages and shifting its focus from vapor products alone to all nicotine products.
Regulations
Feb.22
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Concerns about the effects of vaping on young people and public health were raised at County Hall, the report said, with Cllr Chris Jarman saying it may one day be viewed as “akin to asbestos.” Jarman cited NHS-related research and a case highlighted by Hull University Teaching Hospitals NHS Trust: a 15-year-old admitted with chest pain and breathing difficulty who reported cannabis use and vaping about 500 puffs per day and was diagnosed via CT with “air leak syndrome.”
Feb.27 by 2FIRSTS.ai